Profile cover photo
Profile photo
BioTime
124 followers -
Developing stem cell-based therapies and products in the area of regenerative medicine
Developing stem cell-based therapies and products in the area of regenerative medicine

124 followers
About
BioTime's posts

Post has attachment
Public
BioTime Presents Retinal Restoration Data at ARVO

> Demonstrates Ability to Grow Full-Thickness, 3-D Retinal Tissue

> Tissue is Highly Similar to Natural Human Tissue

$BTX

http://bit.ly/2q5XT2p

Post has attachment
Public
BioTime to Present Additional Data at Upcoming ARVO

> Retinal tissue regeneration presentation added

> OpRegen® presentation scheduled for May 8

$BTX
#RegenMed

http://bit.ly/2psFltC

Post has attachment
Public
BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging

Objective is to quickly establish leadership in the emerging biotechnology field of Aging through pluripotency and iTR™ assets

BioTime continues execution of corporate simplification strategy while remaining focused on Ophthalmology, Aesthetics and Therapeutics Delivery



Post has attachment
Public
BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6

Will Present on the Promise of Pluripotent Cells in Advanced Therapeutics and the Company’s Plans to Develop Applications in Human Aging

$BTX
#regenmed

http://bit.ly/2nAdfHG

Post has attachment
Public


Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8, in Baltimore, Maryland
#ARVO2017
$BTX

Post has attachment
Public

BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
$BTX
http://bit.ly/2mC96nF

Post has attachment
Public
Read GEN's coverage of the opening of our new cGMP cell therapy manufacturing center in Israel.



Post has attachment
Public
BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel

> Supplying OpRegen® for the Ongoing Clinical Trial for the Treatment of Dry Age-Related Macular Degeneration

> Center has Capability to Manufacture Additional BioTime Products-

#RegenMed
$BTX

Post has attachment
Public
Watch BioTime Co-CEO Dr. Michael D. West deliver the Plenary Presentation at the World Stem Cell Summit on Thursday, December 8, 2016:

The Future of Human Aging: Implications of Induced Tissue Regeneration (iTR)

$BTX
#RegMed

http://bit.ly/2hnuI7i
Wait while more posts are being loaded